Atorvastatin inhibits the 5-Lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic apoe knockout mice

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 2, 2013, Pages 205-211

  Yang, Li Xia ^a   Heng, Xu Hua ^a   Guo, Rui Wei ^a   Si, Yan Kun ^a   Qi, Feng ^a   Zhou, Xiao Bin ^a  

^a KUNMING GENERAL HOSPITAL   (China)

Author keywords

5 lipoxygenase; atherosclerosis; Atorvastatin; chemokine CCL3; leukotriene B4; leukotriene D4

Indexed keywords

APOLIPOPROTEIN E; ARACHIDONATE 5 LIPOXYGENASE; ATORVASTATIN; LEUKOTRIENE B4; LEUKOTRIENE D4; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; KNOCKOUT MOUSE; LIPID DIET; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; APOLIPOPROTEINS E; ARACHIDONATE 5-LIPOXYGENASE; ATHEROSCLEROSIS; CHEMOKINE CCL3; CHOLESTEROL, DIETARY; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOTRIENES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; PYRROLES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION;

EID: 84883263852     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182967fc0     Document Type: Article

References (55)

1. Vinereanu D. Risk factors for atherosclerotic disease: Present and future. Herz. 2006;31(suppl 3):5-24.
2. Kriszbacher I, Koppán M, Bódis J. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;353:429-430.
3. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 2010;74:818-826.
4. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol. 2005;16:624-629.
5. Kang BY, Wang W, Palade P, et al. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J Cardiovasc Pharmacol. 2009;54:327-334.
6. Rådmark O, Samuelsson B. 5-Lipoxygenase: Mechanisms of regulation. J Lipid Res. 2009;50(suppl):S40-S45.
7. Jawien J, Korbut R. The current view on the role of leukotrienes in atherogenesis. J Physiol Pharmacol. 2010;61:647-650.
8. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003;100:1238-1243.
9. Tardif JC, L?allier PL, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010;3:298-307.
10. Capra V, Thompson MD, Sala A, et al. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends. Med Res Rev. 2007;27:469-527.
11. Lynch KR, O?Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789-793.
12. Sarau HM, Mong S, Foley JJ, et al. Identification and characterization of leukotriene D4 receptors and signal transduction processes in rat basophilic leukemia cells. J Biol Chem. 1987;262:4034-4041.
13. Heise CE, O?Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275:30531-30536.
14. Takasaki J, Kamohara M, Matsumoto M, et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT (2) receptor. Biochem Biophys Res Commun. 2000;274:316-322.
15. Nothacker HP, Wang Z, Zhu Y, et al. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000;58:1601-1608.
16. Hakonarson H. Role of FLAP and PDE4D in myocardial infarction and stroke: Target discovery and future treatment options. Curr Treat Options Cardiovasc Med. 2006;8:183-192.
17. Zhao L, Moos MP, Gräbner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004; 10:966-973.
18. Aiello RJ, Bourassa PA, Lindsey S, et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002;22:443-449.
19. Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: Potential mechanisms. Arterioscler Thromb Vasc Biol. 2004;24:369-375.
20. Bäck M, Bu DX, Bränström R, et al. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A. 2005;102:17501-17506.
21. Woszczek G, Chen LY, Nagineni S, et al. IL-10 inhibits cysteinyl leukotriene-induced activation of human monocytes and monocytederived dendritic cells. J Immunol. 2008;180:7597-7603.
22. Jawien J, Gajda M, Wo1kow P, et al. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol. 2008;59:633-639.
23. Danforth JM, Strieter RM, Kunkel SL, et al. Macrophage inflammatory protein-1 alpha expression in vivo and in vitro: The role of lipoteichoic acid. Clin Immunol Immunopathol. 1995;74:77-83.
24. Gao JL, Kuhns DB, Tiffany HL, et al. Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor. J Exp Med. 1993;177:1421-1427.
25. Kasama T, Strieter RM, Standiford TJ, et al. Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1 alpha. J Exp Med. 1993;178:63-72.
26. Krzysiek R, Lefèvre EA, Zou W, et al. Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. J Immunol. 1999;162:4455-4463.
27. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2004;36:1882-1886.
28. Rot A, Krieger M, Brunner T, et al. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med. 1992;176:1489-1495.
29. Alam R, Forsythe PA, Stafford S, et al. Macrophage inflammatory protein-1 alpha activates basophils and mast cells. J Exp Med. 1992; 176:781-786.
30. Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: From AIDS to atherosclerosis. Br J Pharmacol. 2011;162:1453-1469.
31. Wilcox JN, Nelken NA, Coughlin SR, et al. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb. 1994;1(suppl 1):S10-S13.
32. Montecucco F, Burger F, Pelli G, et al. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford). 2009;48:233-242.
33. Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. J Am Coll Cardiol. 2007;49:290-297.
34. Okopien B, Krysiak R, Haberka M, et al. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia. J Cardiovasc Pharmacol. 2005;45:314-320.
35. Sakoda K, Yamamoto M, Negishi Y, et al. Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res. 2006;85:520-523.
36. Zhou G, Ge S, Liu D, et al. Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway. Cardiology. 2010;115:221-228.
37. Jawie-n J, Nasta1ek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol. 2004;55:503-517.
38. Piedrahita JA, Zhang SH, Hagaman JR, et al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A. 1992;89:4471-4475.
39. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
40. Bruegel M, Teupser D, Haffner I, et al. Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. Clin Exp Pharmacol Physiol. 2006;33:1144-1149.
41. Veillard NR, Braunersreuther V, Arnaud C, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006;188:51-58.
42. Waehre T, Damås JK, Gullestad L, et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol. 2003;41:1460-1467.
43. Minamino T, Kitakaze M. ER stress in cardiovascular disease. J Mol Cell Cardiol. 2010;48:1105-1110.
44. Knecht TP, Glass CK. The influence of molecular biology on our understanding of lipoprotein metabolism and the pathobiology of atherosclerosis. Adv Genet. 1995;32:141-198.
45. Sikorski K, Czerwoniec A, Bujnicki JM, et al. STAT1 as a novel therapeutical target in pro-Atherogenic signal integration of IFNg, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev. 2011;22:211-219.
46. Manea A, Manea SA, Florea IC, et al. Positive regulation of NADPH oxidase 5 by proinflammatory-related mechanisms in human aortic smooth muscle cells. Free Radic Biol Med. 2012;52:1497-1507.
47. Nigro P, Abe J, Berk BC. Flow shear stress and atherosclerosis: A matter of site specificity. Antioxid Redox Signal. 2011;15:1405-1414.
48. De Caterina R, Massaro M, Scoditti E, et al. Pharmacological modulation of vascular inflammation in atherothrombosis. Ann N Y Acad Sci. 2010; 1207:23-31.
49. Adhikari N, Charles N, Lehmann U, et al. Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury. Curr Atheroscler Rep. 2006;8:252-260.
50. Song XJ, Yang CY, Liu B, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8:564-572.
51. Zhao H, Liao Y, Minamino T, et al. Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens Res. 2008;31:1977-1987.
52. Dong J, Fujii S, Li H, et al. Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-delta. Arterioscler Thromb Vasc Biol. 2005;25:1078-1084.
53. Zhou XX, Gao PJ, Sun BG. Pravastatin attenuates interferon-gamma action via modulation of STAT1 to prevent aortic atherosclerosis in apolipoprotein E-knockout mice. Clin Exp Pharmacol Physiol. 2009;36:373-379.
54. Chandrasekar B, Mummidi S, Mahimainathan L, et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB-And AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem. 2006;281:15099-15109.
55. Viedt C, Shen W, Fei J, et al. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic Res Cardiol. 2003;98:353-361.